13/4
1464

PATENT COOPERATION TREATY

PCT

REC'D 15 MAY 2000

WIPO PCT

INTERNATIONAL SEARCH REPORT

(PCT Artic 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
PF-0610 PCT		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/US 99/23434	06/10/1999	06/10/1998
Applicant		
INCYTE PHARMACEUTICALS, INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readble form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. --

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

al Application No
PCT/US 99/23434

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/53 C12N9/02 C12Q1/68 C12N15/63 A61K38/44
C07K16/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C12Q A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 712 932 A (SUMITOMO CHEMICAL COMPANY, LIMITED) 22 May 1996 (1996-05-22) the whole document ---	1-16,19
A	WO 98 39446 A (HUMAN GENOME SCIENCES, INC.) 11 September 1989 (1989-09-11) page 61, line 15 -page 62, line 4 page 87, line 10 -page 94, line 27 page 96, line 11 -page 102, line 32 sequence listing SEQ ID NO:78 and 201 --- -/--	1-16,19

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
3 February 2000	11. 05. 2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	MONTERO LOPEZ B.

1

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 14328 A (GENENTECH, INC.) 25 March 1999 (1999-03-25) page 32, line 30 -page 33, line 5 page 52, line 32 -page 53, line 5 page 81, line 19 - line 24 page 92, line 9 -page 98, line 36 page 108, line 7 - line 10 page 108, line 20 -page 109, line 12; claims; figures 113,114; examples 47,52-57,60 ---	1-16,19
P,X	WO 99 38881 A (HUMAN GENOME SCIENCES, INC.) 5 August 1999 (1999-08-05) page 85, line 20 -page 87, line 12 page 157, line 12 -page 158, line 5 page 160, line 5 -page 169, line 2 sequence listing SEQ ID NOs.:56 and 124 ---	1-16,19
P,X	R61u001 Database Entry Hsm800581 Accession number AL080080; 23 June 1999 BLUM H. ET AL. XP002129602 the whole document -----	3-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

al Application No
PCT/US 99/23434

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 712932 A	22-05-1996	JP 8140674 A	04-06-1996
		CA 2163136 A	19-05-1996
		US 5928921 A	27-07-1999
		US 5942426 A	24-08-1999
WO 9839446 A		NONE	
WO 9914328 A	25-03-1999	AU 9317898 A	05-04-1999
		AU 9312198 A	05-04-1999
		AU 9484398 A	05-04-1999
		WO 9914327 A	25-03-1999
		WO 9914234 A	25-03-1999
		AU 9395998 A	05-04-1999
		WO 9914241 A	25-03-1999
		AU 9317498 A	05-04-1999
		AU 1126099 A	17-05-1999
		AU 1288399 A	17-05-1999
		WO 9921998 A	06-05-1999
		WO 9921999 A	06-05-1999
		AU 1532499 A	15-06-1999
		WO 9927098 A	03-06-1999
		AU 1703399 A	15-06-1999
		WO 9927100 A	03-06-1999
WO 9938881 A	05-08-1999	AU 2471899 A	16-08-1999

INTERNATIONAL SEARCH REPORT

...tional application No.
PCT/US 99/ 23434

Box I Observati ns wh r certain claims w re found uns archabl (Continuati n of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

2. [X] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [X] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see additional sheet, subject 1.

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 3.

Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

Further defect(s) under Article 17(2)(a):

Continuation of Box 3.

Claims Nos.: 17, 18, 20

Present claims 17, 18 and 20 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not to be found, however, for any specific example of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for claims 17, 18 and 20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:1 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:16 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

2. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:2 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:17 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

3. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:3 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:18 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

4. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:4 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:19 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

5. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:5 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:20 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:6 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:21 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

7. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:7 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:22 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

8. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:8 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:23 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

9. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:10 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:25 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

10. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:11 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:26 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

11. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:12 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:27 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

12. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:13 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:28 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

13. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:14 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:29 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

14. Claims: 1-20 partially

Polypeptide comprising SEQ ID NO:15 and variants thereof; polynucleotide encoding the same and comprising SEQ ID NO:30 and variants thereof; expression vector and host cell comprising them; pharmaceutical composition comprising the polypeptide and its use in treating or preventing a disorder associated with decreased OXRE; antibody binding the polypeptide.

15. Claims: 9-11 partially

Polynucleotide comprising SEQ ID NO:24, fragments thereof and variant having at least 70% identity to it.

PATENT COOPERATION TREA

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 02 August 2000 (02.08.00)	
International application No. PCT/US99/23434	**Applicant's or agent's file reference** PF-0610 PCT
International filing date (day/month/year) 06 October 1999 (06.10.99)	**Priority date** (day/month/year) 06 October 1998 (06.10.98)
Applicant LAL, Preeti et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

05 May 2000 (05.05.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer Juan Cruz
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

15

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PF-0610PCT	**FOR FURTHER ACTION**	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/23434	International filing date *(day/month/year)* 06 OCTOBER 1999	Priority date *(day/month/year)* 06 OCTOBER 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant INCYTE PHARMACEUTICALS, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets.

   ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

   I ☒ Basis of the report

   II ☐ Priority

   III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability

   IV ☐ Lack of unity of invention

   V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI ☐ Certain documents cited

   VII ☐ Certain defects in the international application

   VIII ☐ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
05 MAY 2000	23 OCTOBER 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Dorothea Lawrence for PREMA MERTZ Telephone No. (703) 308-0196

Form PCT/IPEA/409 (cover sheet) (July 1998)★

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/23434

I. Basis of the report

1. With regard to the **elements** of the international application:*

[X] the international application as originally filed

[X] the description:
pages 1-64 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

[X] the claims:
pages 65-66 , as originally filed
pages NONE , as amended (together with any statement) under Article 19
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

[X] the drawings:
pages NONE , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

[X] the sequence listing part of the description:
pages 1-29 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

[ ] the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

[ ] the language of publication of the international application (under Rule 48.3(b)).

[ ] the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

[X] contained in the international application in printed form.

[ ] filed together with the international application in computer readable form.

[ ] furnished subsequently to this Authority in written form.

[ ] furnished subsequently to this Authority in computer readable form.

[ ] The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

[ ] The statement that the information recorded in computer readable form is identical to the writen sequence listing has been furnished.

4. [X] The amendments have resulted in the cancellation of:

[X] the description, pages NONE

[X] the claims, Nos. NONE

[X] the drawings, sheets/~~fig~~ NONE

5. [X] This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

** Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

***Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/23434

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	1-20	YES
	Claims	NONE	NO
Inventive Step (IS)	Claims	1-20	YES
	Claims	NONE	NO
Industrial Applicability (IA)	Claims	1-20	YES
	Claims	NONE	NO

2. citations and explanations (Rule 70.7)

Claims 1-20 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest an oxidoreductase polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-8, 10-15, a polynucleotide encoding said polypeptide, a method of detecting the polynucleotide, a method of producing the polypeptide, an antibody, an agonist, an antagonist, and a method of treatment of a disorder associated with increased expression or activity of oxidoreductase activity by administration of the polypeptide or the antagonist to the polypeptide.

---------- NEW CITATIONS ----------

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/23434

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

CLASSIFICATION:
The International Patent Classification (IPC) and/or the National classification are as listed below:
IPC(7): C12N 5/10, 15/12, 15/52, 15/63, 15/64; C07K 14/47, 16/18; G01N 33/53, 33/567; A61K 38/44
and US Cl.: 514/2, 8, 12; 530/350, 387.1, 387.9; 536/23.1, 23.2, 24.3, 24.31; 435/6, 69.1, 71.1, 71.2, 183, 189, 325, 252.3, 254.11, 471, 320.1

I. BASIS OF REPORT:

5. (Some) amendments are considered to go beyond the disclosure as filed:
NONE

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C12N 15/53, 9/02, C12Q 1/68, C12N 15/63, A61K 38/44, C07K 16/40

A2

(11) International Publication Number: WO 00/20604

(43) International Publication Date: 13 April 2000 (13.04.00)

(21) International Application Number: PCT/US99/23434

(22) International Filing Date: 6 October 1999 (06.10.99)

(30) Priority Data:

60/172,227	6 October 1998 (06.10.98)	US
60/155,202	2 December 1998 (02.12.98)	US
60/123,911	10 March 1999 (10.03.99)	US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US	60/172,227 (CIP)
Filed on	6 October 1998 (06.10.98)
US	60/155,202 (CIP)
Filed on	2 December 1998 (02.12.98)
US	60/123,911 (CIP)
Filed on	10 March 1999 (10.03.99)

(71) Applicant *(for all designated States except US)*: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94702 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). YANG, Junming [CN/US]; 7136 Clarendon Street, San Jose, CA 95129 (US).

(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: OXIDOREDUCTASE MOLECULES

(57) Abstract

The invention provides human oxidoreductase molecules (OXRE) and polynucleotides which identify and encode OXRE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of OXRE.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		